Identification and Validation of Hub Immune-Related Genes in Non-Alcoholic Fatty Liver Disease

References

• Yip TC-F, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76(3):726–734. doi:10.1016/j.jhep.2021.09.024
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60–78.
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023. doi:10.1002/hep.25762
   PubMed Web of Science ®Google Scholar
• Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019;70(6):1885–1888. doi:10.1002/hep.30946
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428.
   PubMed Web of Science ®Google Scholar
• Nati M, Chung KJ, Chavakis T. The role of innate immune cells in nonalcoholic fatty liver disease. J Innate Immun. 2022;14(1):31–41. doi:10.1159/000518407
   PubMed Web of Science ®Google Scholar
• Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. doi:10.3389/fimmu.2014.00177
   PubMed Web of Science ®Google Scholar
• Arrese M, Cabrera D, Kalergis AM, et al. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61(5):1294–1303. doi:10.1007/s10620-016-4049-x
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–257. doi:10.1038/nature16969
   PubMed Web of Science ®Google Scholar
• Hou J, Zhang J, Cui P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest. 2021;131(4). doi:10.1172/JCI135197
   Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Dunn P, Thomas CG, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015. doi:10.1038/sdata.2018.15
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Zhang X, Lan Y, Xu J, et al. CellMarker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2019;47:D721–D728. doi:10.1093/nar/gky900
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Li M, Xu C, Shi J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Gut. 2018;67(12):2169–2180. doi:10.1136/gutjnl-2017-313778
   PubMed Web of Science ®Google Scholar
• Park M, Yoo J-H, Lee Y-S, et al. Extract attenuates non-alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice. Nutrients. 2019;11(3):494. doi:10.3390/nu11030494
   PubMed Web of Science ®Google Scholar
• Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402. doi:10.1172/JCI76738
   PubMed Web of Science ®Google Scholar
• Wang M, Li B, Qin F, et al. Obesity induced Ext1 reduction mediates the occurrence of NAFLD. Biochem Biophys Res Commun. 2022;589:123–130. doi:10.1016/j.bbrc.2021.12.017
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiao G, Ren S, et al. Exosomes from bone marrow mesenchymal stem cells enhance fracture healing through the promotion of osteogenesis and angiogenesis in a rat model of nonunion. Stem Cell Res Ther. 2020;11(1):38. doi:10.1186/s13287-020-1562-9
   PubMed Web of Science ®Google Scholar
• You Y, Liu J, Zhang L, et al. WTAP-mediated m(6)A modification modulates bone marrow mesenchymal stem cells differentiation potential and osteoporosis. Cell Death Dis. 2023;14(1):33. doi:10.1038/s41419-023-05565-x
   PubMed Web of Science ®Google Scholar
• Zhao NQ, Li X-Y, Wang L, et al. Palmitate induces fat accumulation by activating C/EBPβ-mediated G0S2 expression in HepG2 cells. World J Gastroenterol. 2017;23(43):7705–7715. doi:10.3748/wjg.v23.i43.7705
   PubMed Web of Science ®Google Scholar
• Syn WK, Htun Oo Y, Pereira TA, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 2010;51(6):1998–2007. doi:10.1002/hep.23599
   PubMed Web of Science ®Google Scholar
• Rau M, Schilling A-K, Meertens J, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 Cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196(1):97–105. doi:10.4049/jimmunol.1501175
   PubMed Web of Science ®Google Scholar
• du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology. 2015;149(3):635–648.e14. doi:10.1053/j.gastro.2015.05.044
   PubMed Web of Science ®Google Scholar
• Wieser V, Adolph TE, Grander C, et al. Adipose type I interferon signalling protects against metabolic dysfunction. Gut. 2018;67(1):157–165. doi:10.1136/gutjnl-2016-313155
   PubMed Web of Science ®Google Scholar
• Rojek AM, Skowronski MT, Füchtbauer E-M, et al. Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc Natl Acad Sci U S A. 2007;104(9):3609–3614. doi:10.1073/pnas.0610894104
   PubMed Web of Science ®Google Scholar
• Gena P, Mastrodonato M, Portincasa P, et al. Liver glycerol permeability and aquaporin-9 are dysregulated in a murine model of non-alcoholic fatty liver disease. PLoS One. 2013;8(10):e78139. doi:10.1371/journal.pone.0078139
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Gena P, Méndez-Giménez L, et al. Reduced hepatic aquaporin-9 and glycerol permeability are related to insulin resistance in non-alcoholic fatty liver disease. Int J Obes. 2014;38(9):1213–1220. doi:10.1038/ijo.2013.234
   PubMed Web of Science ®Google Scholar
• Wang C, Lv Z-L, Kang Y-J, et al. Aquaporin-9 downregulation prevents steatosis in oleic acid-induced non-alcoholic fatty liver disease cell models. Int J Mol Med. 2013;32(5):1159–1165. doi:10.3892/ijmm.2013.1502
   PubMed Web of Science ®Google Scholar
• Quoc QL, Choi Y, Thi Bich TC, et al. S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma. Exp Mol Med. 2021;53(7):1170–1179. doi:10.1038/s12276-021-00652-5
   PubMed Web of Science ®Google Scholar
• Ding Z, Du F, Averitt V RG, et al. Targeting S100A9 reduces neutrophil recruitment, inflammation and lung damage in abdominal sepsis. Int J Mol Sci. 2021;22(23):12923. doi:10.3390/ijms222312923
   PubMed Web of Science ®Google Scholar
• Marinković G, Koenis DS, de Camp L, et al. S100A9 links inflammation and repair in myocardial infarction. Circ Res. 2020;127(5):664–676. doi:10.1161/CIRCRESAHA.120.315865
   PubMed Web of Science ®Google Scholar
• Agra RM, Fernández-Trasancos Á, Sierra J, et al. Differential association of S100A9, an inflammatory marker, and p53, a cell cycle marker, expression with epicardial adipocyte size in patients with cardiovascular disease. Inflammation. 2014;37(5):1504–1512. doi:10.1007/s10753-014-9876-3
   PubMed Web of Science ®Google Scholar
• Bouma G, Lam-Tse WK, Wierenga-Wolf AF, et al. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes. 2004;53(8):1979–1986. doi:10.2337/diabetes.53.8.1979
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Y, Ming Y, et al. S100A9: a potential biomarker for the progression of non-alcoholic fatty liver disease and the diagnosis of non-alcoholic steatohepatitis. PLoS One. 2015;10(5):e0127352. doi:10.1371/journal.pone.0127352
   PubMed Web of Science ®Google Scholar
• Nies JF, Panzer U. IL-17C/IL-17RE: emergence of a unique axis in T17 biology. Front Immunol. 2020;11:341. doi:10.3389/fimmu.2020.00341
   PubMed Web of Science ®Google Scholar
• Chang SH, Reynolds J, Pappu B, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611–621. doi:10.1016/j.immuni.2011.09.010
   PubMed Web of Science ®Google Scholar
• Krohn S, Nies JF, Kapffer S, et al. IL-17C/IL-17 receptor E signaling in CD4 T cells promotes T17 cell-driven glomerular inflammation. JASN. 2018;29(4):1210–1222. doi:10.1681/ASN.2017090949
   Web of Science ®Google Scholar
• Huang J, Yuan Q, Zhu H, et al. IL-17C/IL-17RE augments T cell function in autoimmune hepatitis. J Immunol. 2017;198(2):669–680. doi:10.4049/jimmunol.1600977
   PubMed Web of Science ®Google Scholar
• Liao R, Sun J, Wu H, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32:3. doi:10.1186/1756-9966-32-3
   PubMed Web of Science ®Google Scholar
• Tsukumo S-I, Unno M, Muto A, et al. Bach2 maintains T cells in a naive state by suppressing effector memory-related genes. Proc Natl Acad Sci U S A. 2013;110(26):10735–10740. doi:10.1073/pnas.1306691110
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang H, Wang Y, et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol. 2021;75(6):1271–1283. doi:10.1016/j.jhep.2021.07.032
   PubMed Web of Science ®Google Scholar